Pfizer Inc’s Ibrance Drug Proves It Can Slow down Progression of Breast Cancer

Pfizer Inc’s Ibrance Drug Proves It Can Slow down Progression of Breast Cancer

Pfizer Inc's Ibrance drug in a phase-III trial confirmed that when combined with hormone remedy, it can double the period of illness management for ladies with most typical sort of breast cancers.

It was said that interim evaluation sufferers that were given Ibrance and AstraZeneca Plc's Faslodex (fulvestrant), an extensively used remedy to dam estrogen, were able to survive 9.2 months more as compared to other cancer sufferers.

The trial was introduced at a gathering of the American Society of Clinical Oncology. The trial included 521 sufferers whose breast most cancers were categorized as estrogen-receptor constructive, human epidermal progress issue receptor 2-negative. This class accounts for about 75% of all breast cancers.

Pfizer Cleared of Liability in US trial claiming Zoloft can Cause Birth Defects

Pfizer Cleared of Liability in US trial claiming Zoloft can Cause Birth Defects

On Friday, Pfizer was given a clean chit in the first US trial claiming that its antidepressant Zoloft can cause birth defects in children who are born to women who take the drug during pregnancy.

Plaintiff Kristyn Pesante has accused Pfizer for not revealing Zoloft's risks in order to boost sales. She said that owing to the company's failure for not warning about the drug's side effects, her son was born with a rare, serious congenital heart problem.

For a week, the trial has been conducted in St. Louis, Missouri. Pesante has asked for both compensatory and punitive damages from the company. A number of lawsuits have been filed against Zoloft claiming that it causes cardiac and other birth defects.

Pfizer’s Breast cancer Drug Ibrance shows Impressive Results

Pfizer’s Breast cancer Drug Ibrance shows Impressive Results

Earlier, Pfizer's breast cancer drug Ibrance's clinical trial was delayed due to some issues based on the independent Data Monitoring Committee's (DMC) assessment. After the issues have been resolved, the clinical trial of the drug were resumed.

Ibrance, also known as palbociclib, is Pfizer's experimental breast cancer drug. It is undergoing phase 3 study called PALOMA-3 trial. The drug has met its primary ends and showed improvements in Progression-Free Survival of PFS, according to reports.

Pfizer to Cease its Vaccines Sales Operations in China

Pfizer to Cease its Vaccines Sales Operations in China

U. S. pharmaceutical corporation Pfizer said that it is planning to cease its vaccines sales operations in China. According to the company, the Chinese government was not keen on renewal of an import license for one of its products.

Pfizer said that this move will cause a shortage of the treatment in China. The company notified that the license for Prevenar has expired. Prevenar is a vaccine that protects children against pneumococcal disease that can lead to pneumonia.

"Based on a careful assessment of this situation, we have decided to cease our vaccines commercial operations in China at this time, effective immediately", Pfizer spokeswoman Trupti Wagh said in comments emailed to Reuters.

Pfizer breast cancer drug gets early FDA approval

PfizerWashington: Federal health regulators have approved a highly anticipated medicine from Pfizer Inc to treat postmenopausal women with a certain type of advanced breast cancer who have not already taken other drugs.

The Food and Drug Administration yesterday approved Ibrance for women who have tumors that do not contain a protein known as HER-2. Ibrance, known generically as palbociclib, works by blocking molecules linked to cancer cell growth.

Pharmaceutical industry analysts expect Ibrance to grow into a mega-blockbuster, with annual sales as high as USD 4 billion by 2020.

Pfizer Q1 Net dips 3% at Rs 46 cr

PfizerNew Delhi: Drug firm Pfizer Thursday reported 3.10 percent decline in net profit at Rs 46.15 crore for the first quarter ended June 30, 2014.

The company had posted a net profit of Rs 47.63 crore in the same period of previous fiscal.

Net sales of the company, however, rose to Rs 239.85 crore during the first quarter, as compared to Rs 237.53 crore in the same period of previous fiscal, Pfizer Ltd said in a filing to the BSE.

Shares of Pfizer today closed at Rs 1,412.05 apiece on the BSE, down 0.45 percent from previous close.--- PTI

Pfizer, Novartis might bid for Onyx

Pfizer, Novartis might bid for OnyxIt is believed that pharmaceutical companies such as Pfizer Inc and Novartis AG might be planning to bid for Onyx Pharmaceuticals.

Onyx Pharmaceuticals might ensure a strong revenue stream through tis cancer drugs. Onyx focuses on biotechnology and has a market value of around $9.5 billion. The company management has decided to offer the stake following expression of interests from some companies, whose names were not disclosed.

US firms ask Government to urge India to open markets

US firms ask Government to urge India to open marketsIndustry players in the US have asked the United Sates Government to put pressure on the Indian government to open up its markets for more US exports.

US firms said that the Indian government should be asked to alter its high-tech, agricultural and pharmaceutical policies that allegedly block imports from the US into the country. They claim that some of the US policies are also affecting their patent rights. They described some of the policies as protectionist that affects the US job creation.

Pharma tops list of FDI proposals approved by govt.

Pharma tops list of FDI proposals approved by govt.The pharmaceutical sector topped the list of foreign direct investment (FDI) proposals that the government cleared on Tuesday.

The union government yesterday cleared a total of 21 FDI proposals, including eight proposals from the pharmaceutical sector. Total worth of all the cleared proposals is estimated at Rs 2,410 crore, out of which brownfield pharmaceutical sector accounts for Rs 1,842.55 crore.

Pfizer exits deal to sell Biocon’s insulin

Pfizer exits deal to sell Biocon’s insulinWorld's largest drugmaker, Pfizer has announced its exit from a deal under which it was to sell insulin products made by Biocon, which is India's leading biotechnology company.

The two companies released a joint statement announcing the scrapping of the deal and cited individual priorities as the reason for ending of the deal. Biocon was expected to earn millions of dollars in royalties through the deal and now it is left without any partner to distribute its products in the US and other global markets.

Pfizer Reveals a Net Profit of Rs 41.24 Crore

Pfizer Reveals a Net Profit of Rs 41.24 CroreAccording to reports, the drug firm Pfizer has revealed a net profit of Rs 41.24, for the quarter, which ended on the 30th of June, 2011. The company had a net profit of 34.69 crore for the quarter which ended on the 31st of May, the previous year.

Also, the net sales of the company for the quarter that ended on the 30th of June 2011 is at Rs 241.87 crore, which was Rs 212.33 crore for the quarter ended May 31, 2010.

Hold Pfizer With Stop Loss Of Rs 1020

Hold Pfizer With Stop Loss Of Rs 1020Technical analyst MB Singh has maintained 'hold' rating on Pfizer Limited stock.

The analyst said that the investors can hold the stock with a stop loss of Rs 1020.

The analyst added that the investors can exit the stock on rally.

The stock of the company, on January 11, closed at Rs 1123.25 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 1310 and a low of Rs 862.40 on BSE.

Current EPS & P/E ratio stood at 51.07 and 22.81 respectively.

Pfizer to close eight plants worldwide over five years

pfizerIt will trim its workforce by 6,000 people and close eight plants worldwide over five years, U. S. pharmaceutical giant Pfizer Global Manufacturing said on Tuesday.

The staff reduction is part of its plan to reshape its plant network following its 2009 takeover of Wyeth, The New York company said in an announcement on its Web site.

It was also reported that eight plants will be shuttered in Ireland, Puerto Rico and the United States by the end of 2015. Operations will be cut back at six other plants in Germany, Ireland, Puerto Rico, the United Kingdom and the United States.

Pfizer Q4 results fall

Pfizer-LtdPfizer Ltd. has reported a fall in its standalone profit figures. The results are for the fourth quarter.

The net profit of the company was Rs. 25.73 crore, which boils down to Rs. 8.62 per share. It is 15 per cent lesser than the corresponding figure of the last year. During the last fiscal, it had shown profit of Rs. 30.23 crore.

Interestingly, this decline is even after the company posted an increase in its revenue.

12% Goods and Services Tax (GST) questionable: States

12% Goods and Services Tax (GST) questionable: StatesThe Empowered Committee of State Finance Ministers today indicated that the proposed implementation of the Goods and Services Tax (GST) would be postponed as the states raised questions about the methodology applied by the Thirteenth Finance Commission taskforce. A new date is expected to be announced later.

Strides Arcolab enters alliance with Pfizer

Strides Arcolab enters alliance with PfizerStrides Arcolab, the Bangalore based Pharmaceutical company, has entered into a deal for licensing and supply for medicines with the World's largest drug maker Pfizer.

The deal covers injectables and some oral products from the Indian company along with forty off patent medicines for sale in the US. The financial details of the deal were not disclosed. The first product of the alliance is to be launched as early as 2010.

U.S. FDA Still Not Satisfied of Pfizer vaccine

PfizerThe U. S. Food and Drug Administration have still not given a green signal to Prevnar vaccine of Pfizer. This children’s vaccine has been developed to fight pneumonia and meningitis, but it seems that the regulator is not happy with the vaccine just as yet.

Pfizer obtained this vaccine from Wyeth, after acquiring Wyeth for $67 billion. Now, Pfizer wants FDA’s acceptance to market Prevnar 13 as a vaccine for infants and toddlers.

Clinical Trial for Experimental Lung Cancer Drug Ended by Pfizer

Pfizer On Tuesday, Pfizer Inc, the pharmaceutical giant, announced that it has ended a Phase III trial which it was undertaking for figitumumab, an experimental drug for lung cancer, which has been tied to an unusual and unexpected number of deaths during testing among patients who were placed on it.

Pfizer Takes Legal Action Against Dr Reddy’s Over Lipitor

Pfizer Takes Legal Action Dr Reddy’s Over LipitorGlobal pharmaceutical major Pfizer has taken legal against Dr Reddy's Laboratories (DRL) over its anti-cholesterol medicine Lipitor, which is the world's largest selling drug having sales worth more than $8 billion.

Pfizer asked a judge to forbid sales of generic variants of 'Lipitor' until 2017.

Hyderabad-based Dr Reddy's has formulated Lipitor's generic variant, and has sought the USFDA's nod to sell copies of Lipitor in the market.

Pfizers profit, earnings, drop despite Viagra boom

Pfizers profit, earnings, drop despite Viagra boom Washington - Pfizer Inc, the worlds biggest drugmaker, Tuesday said profits were down 2 per cent and revenues were down 8.3 per cent compared to first quarter 2008 despite blockbuster drugs like the impotence pill Viagra and cholesterol-busting Lipitor. Net income dropped to 2.73 billion dollars, while revenues were down to 10.9 billion dollars, the company said.

Profits were eroded by the rising dollar, which lowered income from abroad, the company said.

Syndicate content